Table 4.
Vasopressin group median (1st, 3rd quartile), n |
Norepinephrine group median (1st, 3rd quartile), n |
||||||||
---|---|---|---|---|---|---|---|---|---|
Time | Baseline | 6 hours | Day 2 | Day 4 | Baseline | 6 hours | Day 2 | Day 4 | P value |
Troponin I (µg/L) | 0.07 (0.0, 0.54) 48 |
0.11 (0.0, 0.71) 44 |
0.15 (0.0, 0.60) 39 |
0.03 (0.0, 0.24) 35 |
0.20 (0.0, 0.39) 44 |
0.35 (0.10,0.70) 39 |
0.21 (0.0, 0.60) 37 |
0.14 (0.0, 0.43) 33 |
0.230 |
Troponin T (µg/L) |
0.06 (0.02, 0.09) 14 |
0.06 (0.0, 0.14) 11 |
0.03 (0.0, 0.09) 12 |
0.00 (0.0, 0.02) 9 |
0.01 (0.0, 0.42) 11 |
0.06 (0.0, 0.38) 10 |
0.07 (0.01, 0.35) 12 |
0.13 (0.01, 0.39) 8 |
0.360 |
CK (U/L) |
204 (61, 487) 54 |
208 (54, 435) 48 |
190 (36, 452) 50 |
69 (21, 189) 45 |
184 (60, 309) 46 |
192 (68, 438) 46 |
147 (41, 296) 45 |
46 (21, 222) 39 |
0.985 |
CK-MB (µg/L) |
4.0 (1.6, 6.9) 16 |
3.0 (1.3, 6.0) 15 |
5.0 (1.0, 16.0) 14 |
1.4 (0.0, 3.1) 14 |
4.3 (1.0, 8.0) 14 |
2.6 (1.8, 17.2) 12 |
4.7 (2.0, 16.0) 13 |
1.9 (1.0, 6.0) 10 |
0.396 |
Serum levels of troponin, creatine kinase (CK), and creatine kinase-MB (CK-MB) at each time point. P value is based on linear mixed-effects regression model and is for the null hypothesis of no difference in troponin/CK/CK-MB level between the treatment groups at 6 hours, day 2, and day 4, adjusted for baseline value. Outcome variables were log transformed if they were not normally distributed.